Clinical trials: Angina, Microvascular
Metabolic Syndrome X
Mechanisms of Cerebrovascular Control
The objective of this study is to identify insulin-specific cerebral blood flow (CBF) control mechanisms, and establish cerebrovascular responsive baseline in younger (18-45 yrs) metabolic syndrome adults (MetSyn) who are at…
- Trial name
- NCT02936687
- Testing
- NOS Inhibition, ET-1 Inhibition, 3 Tesla MRI
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Microvascular Angina
Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction
The aim of this study is to explore effects of long term treatment with ACE-inhibitor on the small vessel function assessed by coronary flow reserve (CFR) by transthoracic echocardiography and flow mediated dilation in…
- Trial name
- NCT02525081
- Testing
- Ramipril (ACE-inhibitor)
- Where
- Denmark
- Volunteers
- 63 people
- Sponsor
- Bispebjerg Hospital
Metabolic Syndrome X
Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion
The Metabolic Syndrome is a high prevalence disease worldwide. About a quarter of the adult population suffers the disease. Dapagliflozin is an inhibitor of the sodium-glucose co-transporter SGLT2 in the kidney and is a novel…
- Trial name
- NCT02113241
- Testing
- Dapagliflozin
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- University of Guadalajara
Coronary Microvascular Disease
The Euro-CRAFT Registry
The Euro-CRAFT Registry is a prospective, multicentric, international registry of patients undergoing functional assessment of the coronary microcirculation using the continuous thermodilution technique.
- Trial name
- Euro-CRAFT (NCT05805462)
- Where
- 19 sites in Belgium, Denmark and 6 more
- Volunteers
- 671 people
- Sponsor
- CoreAalst BV
Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
This is a randomized, double-Blind, placebo-controlled study to evaluate the efficacy and safety of exaluren in Alport Syndrome patients with nonsense mutations in COL4A3/4/5 genes.
- Trial name
- NCT07523581
- Testing
- Exaluren
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 24 people
- Sponsor
- Eloxx Pharmaceuticals, Inc.
Safety Issues, Efficacy, Self
Lower Silesia Sinus Reducer Registry
Lower Silesia Sinus Reducer Registry is a , single-center, single-arm registry including patients with chronic disabling refractory angina pectoris (Canadian Cardiovascular Society [CCS] classes 2-4) despite maximally tolerated…
- Trial name
- LSSRR (NCT06288165)
- Testing
- Coronary Sinus Reducer Implantation
- Where
- 2 sites in Poland
- Volunteers
- 200 people
- Sponsor
- Miedziowe Centrum Zdrowia SA
Coronary Artery Disease, Coronary Stenosis
Measuring Blood Flow in Heart Vessels With a New Fibre Optic Sensor
The purpose of this investigation is to see if the newly developed "iKOs™ microcatheter" can safely and accurately measure flow and pressure within the heart arteries of 10 patients undergoing angiogram and pressure wire tests.
- Conditions
- Coronary Artery Disease, Coronary Stenosis, Coronary Microvascular Disease
- Trial name
- NCT05346458
- Testing
- Intra coronary rapid-exchange iKOs microcatheter intervention
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Queen Mary University of London
XIAP Deficiency, NLRC4-MAS
Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension
This is an open-label extension study for patients previously enrolled in the AB2 Bio Ltd. ongoing Phase III clinical trial NLRC4/XIAP.2016.001 (IND N° 127953).
- Trial name
- NCT03512314
- Testing
- Tadekinig alfa
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 11 people
- Sponsor
- AB2 Bio Ltd.
Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR)
The Effect of IV Cangrelor and Oral Ticagrelor Study
Major heart attacks are caused by a number of factors, the two major of which are furring up of a coronary artery with atheroma and then sudden clot formation on this area leading to a blockage and interruption of blood flow.
- Conditions
- Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO), ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT02733341
- Testing
- Cangrelor, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Obesity, Metabolic Syndrome X
Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity
Obesity is common (>30% of US adults), contributes to substantial morbidity and mortality, but is difficult to treat. Partly this is due to the transient, arduous and modest nature of lifestyle interventions.
- Trial name
- REVIVE (NCT01351753)
- Testing
- Metformin, Orlistat, Topiramate
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Iowa
COVID-19 Associated Cardiac Involvement, Remodeling, Left Ventricle
Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
Long COVID or Postacute sequelae of COVID-19 infection (PASC) are increasingly recognised complications, defined by lingering symptoms, not present prior to the infection, typically persisting for more than 4 weeks.
- Conditions
- COVID-19 Associated Cardiac Involvement, Remodeling, Left Ventricle, Remodeling, Vascular, Left Ventricular Dysfunction
- Trial name
- MYOFLAME-19 (NCT05619653)
- Testing
- Prednisolone, Losartan
- Where
- 5 sites in Austria, Germany
- Volunteers
- 279 people
- Sponsor
- Valentina Puentmann
Angina (Stable), Ischemic Heart Disease (IHD)
Angina After PCI: a Systems Medicine Study
Angina may persist or recur in patients treated by coronary angioplasty. The angioplasty involves a balloon treatment to open a blocked heart blood vessel and usually a stent (thin metal tube) is placed.
- Trial name
- CorMicA-PCI (NCT06854302)
- Testing
- Cardiovascular magnetic resonance imaging, Coronary physiology
- Where
- 4 sites in United Kingdom
- Volunteers
- 600 people
- Sponsor
- NHS National Waiting Times Centre Board
Refractory Angina, Microvascular Angina
Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.
To demonstrate the feasibility and efficacy of the CS Reducer for the treatment of patients with ischaemia and non-obstructed coronary arteries (INOCA) and coronary microvascular dysfunction (CMD) and through a nested mechanistic…
- Conditions
- Refractory Angina, Microvascular Angina, Microvascular Coronary Artery Disease, Coronary Disease
- Trial name
- REMEDY-PILOT (NCT05492110)
- Testing
- Coronary sinus reducer, Invasive coronary physiology
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- Imperial College London
Exercise Therapy, Metabolic Syndrome X
Exercise Training Effects on Metabolic Syndrome: Interactions With Medication
To analyze the effects of different exercise training modalities (continuous, intervallic, and resistance training) on cardiorespiratory and metabolic fitness of metabolic syndrome patients when this training interacts with their…
- Conditions
- Exercise Therapy, Metabolic Syndrome X, Cardiorespiratory Fitness
- Trial name
- METSYND (NCT03019796)
- Testing
- MEDICATION AND EXERCISE TRAINING
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- University of Castilla-La Mancha
NLRC4-MAS, XIAP Deficiency
Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency
This is a Phase 3 study to assess the safety and efficacy of Tadekinig alfa in patients with monogenic, interleukin-18 (IL 18) driven autoinflammation due to Nucleotide-binding oligomerization domain, leucine-rich repeat and…
- Trial name
- NCT03113760
- Testing
- Tadekinig alfa, 0.9% sodium chloride
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 15 people
- Sponsor
- AB2 Bio Ltd.
Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
The aim of this study is to establish the diagnostic performance of the AngioAI+ System (AngioInsight, Inc, USA) for estimating: 1. Fractional flow reserve (FFR) and 2.
- Trial name
- SMARTFLOW (NCT07676097)
- Testing
- Patients with intermediate coronary artery stenosis with clinically indicated FFR assessment., Microvascular assessment
- Where
- 9 sites in United States
- Volunteers
- 620 people
- Sponsor
- AngioInsight
Intermittent Claudication, Metabolic Syndrome X
Prevalence of Metabolic Syndrome in Patients With Intermittent Claudication
Metabolic syndrome, a group of cardiovascular risk factors related to insulin resistance, is a major determinant of cardiovascular mortality. Intermittent claudication is a symptom of an early stage of atherosclerosis.
- Trial name
- NCT00946868
- Where
- Brazil
- Volunteers
- 170 people
- Sponsor
- University of Sao Paulo
Depressive Symptoms, Metabolic Syndrome X
Reducing Disparities in Late Life Depression and Metabolic Syndrome
Linkages between depression and cardiovascular disease have been well documented. These appear to be more than associations, and may reflect causal relationships through a number of proposed pathways, including decreased physical…
- Conditions
- Depressive Symptoms, Metabolic Syndrome X, Overweight, Obesity
- Trial name
- BRIGHTEN-Heart (NCT01428791)
- Testing
- Generations older adult membership program, BRIGHTEN Heart Virtual Team intervention
- Where
- 2 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Hypertension, Metabolic Syndrome X
Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities
The objective of the study is to compare PPAR activities (increase of adiponectin level) between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome.
- Trial name
- NCT00242814
- Testing
- Micardis, Amlodipine, Abdominal biopsy
- Where
- 31 sites in France
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Angina Pectoris, Myocardial Ischemia
Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)
VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX…
- Conditions
- Angina Pectoris, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases
- Trial name
- SERRA-I US (NCT07449325)
- Testing
- A-FLUX Reducer System
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- VahatiCor, Inc.